If all goes well, the first malaria drug developed by Thai researchers could reach human clinical trials at the beginning of next year.
The drug, dubbed P218, is the product of research carried out by a
group at BIOTEC
, a
research centre created by the Thai government to generate biotechnology
innovations.
Although several international partners, including Medicines for Malaria Venture (MMV), Yale University, London School of Hygiene & Tropical Medicine and Monash University in Australia, have been involved along the way, it was BIOTEC that conducted the initial research that has eventually allowed new drug candidates, such as P218, to be developed.
See the rest of the story here.
Comments